

S2 Table. Patient characteristics according to adjuvant chemotherapy

	Adjuvant chemotherapy (-)	Adjuvant chemotherapy (+)	p-value
No. of patients	107	108	
Age, median (range, mo)	70.0 (32-92)	59.5 (30-102)	<0.001
ECOG			<0.001
0	24 (22.4)	53 (49.1)	
1	58 (54.2)	38 (35.2)	
2	2 (1.9)	0	
Not assessed	23 (21.5)	17 (15.7)	
Laterality			0.439
Unilateral, right	49 (45.8)	47 (43.5)	
Unilateral, left	50 (46.7)	56 (51.9)	
Bilateral	0	1 (0.9)	
Not assessed	8 (7.5)	4 (3.7)	
Multiplicity			0.100
No	95 (88.8)	94 (87.0)	
Yes	2 (1.9)	8 (7.4)	
Not assessed	10 (9.3)	6 (5.6)	
Histology			0.123
Invasive ductal carcinoma	79 (73.8)	95 (88.8)	
Invasive lobular carcinoma	0	1 (0.9)	
Mucinous carcinoma	4 (3.7)	4 (3.7)	
Papillary carcinoma	11 (10.3)	2 (1.9)	
Cribriform carcinoma	2 (1.9)	1 (0.9)	
Sarcoma	3 (2.8)	0	
Others	2 (1.9)	1 (0.9)	
Carcinoma	1 (0.9)	1 (0.9)	
Not assessed	5 (4.7)	3 (2.8)	
Grade			<0.001
Well	22 (20.6)	13 (12.0)	
Moderate	36 (33.6)	59 (54.6)	
Poor	11 (10.3)	20 (18.5)	
Not assessed	38 (35.5)	16 (14.8)	
Stage			<0.001
I	49 (45.8)	19 (17.6)	
II	43 (40.2)	54 (50.0)	
III	9 (8.4)	31 (28.7)	
Not assessed	6 (5.6)	4 (3.7)	
T category			0.171
Tis	1 (0.9)	1 (0.9)	
T1	58 (54.2)	52 (48.1)	
T2	40 (37.4)	46 (42.6)	
T3	0	5 (4.6)	
T4	2 (1.9)	2 (1.9)	
Not assessed	6 (5.6)	2 (1.9)	
N category			<0.001
0	71 (66.4)	33 (30.6)	
1	15 (14.0)	41 (38.0)	

2	6 (5.6)	13 (12.0)	
3	2 (1.9)	15 (13.9)	
Not assessed	13 (12.1)	6 (5.6)	
Lymphatic invasion			0.002
No	54 (50.5)	39 (36.1)	
Yes	22 (20.6)	47 (43.5)	
Not assessed	31 (29.0)	22 (20.4)	
Vascular invasion			0.047
No	59 (55.1)	58 (53.7)	
Yes	15 (14.0)	28 (25.9)	
Not assessed	33 (30.8)	22 (20.4)	
Perineural invasion			0.049
No	50 (46.7)	62 (57.4)	
Yes	4 (3.7)	9 (8.3)	
Not assessed	53 (49.5)	37 (34.3)	
ER			0.044
Negative	8 (7.5)	4 (3.7)	
Positive	87 (81.3)	100 (92.6)	
Not assessed	12 (11.2)	4 (3.7)	
PR			0.143
Negative	18 (16.8)	15 (13.9)	
Positive	77 (72.0)	88 (81.5)	
Not assessed	12 (11.2)	5 (4.6)	
HER2			0.196
0	49 (45.8)	43 (39.8)	
1+	19 (17.8)	22 (20.4)	
2+	13 (12.1)	23 (21.3)	
3+	9 (8.4)	11 (10.2)	
Not assessed	17 (15.9)	9 (8.3)	
Ki-67, median (range)	14.1 (7.8-35.0)	20.0 (10.0-30.0)	0.352
Classification			0.056
HR (+)	80 (74.8)	84 (77.8)	
HER2 (+)	9 (8.4)	17 (15.7)	
TNBC	6 (5.6)	3 (2.8)	
Not assessed	12 (11.2)	4 (3.7)	
Subtype			0.079
Luminal A	30 (28.0)	28 (25.9)	
Luminal B	16 (15.0)	27 (25.0)	
HER2 positive	9 (8.4)	17 (15.7)	
TNBC	6 (5.6)	3 (2.8)	
Not assessed	46 (43.0)	33 (30.6)	
Operation			0.011
MRM	69 (64.5)	88 (81.5)	
Total mastectomy	24 (22.4)	17 (15.7)	
BCS	10 (9.3)	1 (0.9)	
Node excision	1 (0.9)	1 (0.9)	
Not assessed	3 (2.8)	1 (0.9)	
LN dissection			0.011
ANLD (axillary LN dissection)	53 (51.0)	78 (72.9)	

SLNB (sentinal LN Bx.)	34 (32.7)	18 (16.8)	
Not done	9 (8.7)	5 (4.7)	
Not assessed	8 (7.7)	6 (5.6)	
Neoadjuvant chemotherapy			0.486
No	101 (94.4)	105 (97.2)	
Yes	6 (5.6)	3 (2.8)	
Adjuvant Radiation			0.009
No	87 (81.3)	68 (63.6)	
Yes	16 (15.0)	35 (32.7)	
Not assessed	4 (3.7)	4 (3.7)	
Adjuvant endocrine therapy			0.993
No	12 (12.9)	13 (12.7)	
Yes	78 (83.9)	86 (84.3)	
Not assessed	3 (3.2)	3 (2.9)	

Values are presented as number (%) unless otherwise indicated. ALND, axillary lymph node dissection; BCS, breast conserving surgery; Bx, biopsy; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LN, lymph node; MRM, modified radical mastectomy; PR, progesterone receptor; SLNB, sentinel lymph node biopsy; TNBC, triple-negative breast cancer.